MABTHERA (rituximab), monoclonal antibodies

Minor improvement in the remission induction strategy for granulomatosis with polyangiitis and severe active microscopic polyangiitis

• MABTHERA now has Marketing Authorisation, in combination with glucocorticoids, in remission induction therapy in adult patients with granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA).

• It has a potential benefit relative to oral cyclophosphamide in patients in relapse.

• There was no evidence of impact on fertility in patients of childbearing age.